Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

Rhea-AI Summary

Nanobiotix (Euronext: NANO, NASDAQ: NBTX) published its regulatory announcement as of December 31, 2021. The report states that there are 34,825,872 outstanding shares and 36,003,389 total voting rights gross. The net voting rights amount to 35,987,933. The figures are in compliance with French Commercial Code and the regulations of the French Financial Markets Authority. The company is developing its lead product candidate, NBTXR3, aiming to transform oncology treatment outcomes.

Positive

• Market authorization achieved in Europe for NBTXR3 under the brand name Hensify®.
• Ownership of over 30 patents associated with various nanotechnology platforms.

Negative

• None.

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des Marchés Financiers (French Financial Markets Authority)

PARIS--(BUSINESS WIRE)-- Regulatory News:

Nanobiotix (Paris:NANO) (NASDAQ:NBTX):

Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights
		Total voting rights, gross (1)	Total voting rights, net (2)
December 31, 2021	34,825,872	36,003,389	35,987,933

⁽¹⁾ The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

⁽²⁾ The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

***

About NANOBIOTIX: http://www.nanobiotix.com
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity.

The company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life. Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, Switzerland, and Germany. Nanobiotix has been listed on Euronext: Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

The company's resources are primarily devoted to the development of its lead product candidate–NBTXR3—which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.

For more information about Nanobiotix, visit us at http://www.nanobiotix.com or follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220111005125/en/

Nanobiotix

Nanobiotix Communications

Brandon Owens

VP, Communications

+1 (617) 852-4835

contact@nanobiotix.com

Nanobiotix Investor Relations

Kate McNeil

SVP, Investor Relations

+1 (609) 678-7388

investors@nanobiotix.com

Media Relations

France – Ulysse Communication

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51

plgermain@ulysse-communication.com

US – Porter Novelli

Dan Childs

+1 (781) 888-5106

dan.childs@porternovelli.com

Source: Nanobiotix

FAQ

What is the total number of voting rights for Nanobiotix as of December 31, 2021?

The total number of voting rights for Nanobiotix as of December 31, 2021, is 36,003,389 gross and 35,987,933 net.

What is the significance of the 34,825,872 outstanding shares for Nanobiotix?

The 34,825,872 outstanding shares indicate the total amount of shares currently held by all shareholders.

What is NBTXR3 and its relevance to Nanobiotix?

NBTXR3 is the lead product candidate of Nanobiotix, designed to improve treatment outcomes in oncology and has received market authorization in Europe.

Where can I find more information about Nanobiotix's products and technology?

More information about Nanobiotix's products and technology can be found on their official website at www.nanobiotix.com.